Retinal Imaging in Alzheimer’s and Neurodegenerative Diseases

Peter J. Snyder  
*University of Rhode Island*, pjsnyder@uri.edu

Jessica Alber  
*University of Rhode Island*, jalber@uri.edu

Clemens Alt

Lisa J. Bain

Brett E. Bouma

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.uri.edu/bps_facpubs](https://digitalcommons.uri.edu/bps_facpubs)

Citation/Publisher Attribution


This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association


biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer’s and other brain diseases, including a discussion of future directions for this area of study.

KEYWORDS
Alzheimer's disease, biomarkers, early detection, eye, neurodegeneration, retina, retinal imaging